Take the next step with Adempas
Adempas is the first and only treatment approved for both PAH (WHO Group 1) and CTEPH (WHO Group 4).*
*Adempas is approved to treat adults with:
- Chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) treated with surgery but who continue to have high pulmonary blood pressure (persistent) or it comes back after surgery (recurrent), or that cannot be treated with surgery (inoperable)
- Pulmonary arterial hypertension (PAH) (WHO Group 1)
The Adempas clinical studies included mostly patients with WHO functional class II-III symptoms. It is not known if Adempas is safe and effective in children.
WHO=World Health Organization
The support you need with Aim
The Aim Patient Support Program offers support to guide you throughout your journey with PAH and CTEPH.